Transaction DateRecipientSharesTypePriceValue
21st October 2020Benjamin Wolin21,615Exercise of derivative$0.00
21st October 2020Benjamin Wolin9,441Payment by withholding$27.04$255,284.64
4th September 2020Mark H Ravich10,000Other acquisition or disposition$1.16$11,600.00
4th September 2020Mark H Ravich16,000Other acquisition or disposition$1.16$18,560.00
4th September 2020Benjamin Wolin9,259Exercise of derivative$0.00
4th September 2020Mark H Ravich9,000Other acquisition or disposition$1.16$10,440.00
4th September 2020Benjamin Wolin3,993Payment by withholding$22.29$89,003.97
4th September 2020Mark H Ravich25,000Other acquisition or disposition$1.22$30,500.00
3rd September 2020Mark H Ravich173,905Other acquisition or disposition$1.21$210,425.05
3rd September 2020Mark H Ravich11,000Other acquisition or disposition$1.21$13,310.00
Rockwell Medical
Rockwell Medical logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995.


Ticker: RMTI
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1041024
Employees: 299
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $27 M (0%)
Inventory, Net: $5 M (24%)
Assets, Current: $52 M (39%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $561 Th (28%)
Assets: $59 M (32%)
Accounts Payable, Current: $3 M (9%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $11 M (-7%)
Liabilities: $42 M (76%)
Common Stock, Shares, Issued: $70 M (7%)
Retained Earnings (Accumulated Deficit): $321 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $46 Th (-12%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $59 M (32%)
Cost of Revenue: $15 M (-49%)
Gross Margin: $881 Th (-55%)
Research and Development: $2 M (-52%)
Sales and Marketing: $2 M (-50%)
General and Administrative Expenses: $3 M (-64%)
Operating Income/Loss: $6 M (-58%)